What the Complete Spravato Treatment Journey Looks Like: From Induction to Maintenance at Innovative MindCare in Chicago and Downers Grove

Starting a new treatment for depression-especially after other medications have not provided adequate relief-can feel uncertain. Knowing what lies ahead at each stage can make the process feel more manageable and help you approach care with confidence. For adults exploring Spravato treatment in Chicago, understanding the full journey from initial evaluation through long-term maintenance is an important first step toward making an informed decision about your mental health care.

At Innovative MindCare, with locations in Chicago and Downers Grove, Illinois, the Spravato treatment process follows a clearly defined, medically supervised protocol. This guide walks through what patients can expect at every phase-so there are no surprises along the way.

What Is Spravato and Who May Benefit From It?

Spravato (esketamine nasal spray) is an FDA-approved medication designed specifically for two clinical indications: treatment-resistant depression (TRD) in adults and depressive symptoms in adults with major depressive disorder (MDD) who have suicidal thoughts or actions. It is not a general antidepressant and is not interchangeable with other ketamine-based treatments. Spravato has its own distinct regulatory approval, clinical protocols, and safety requirements.

Because of its specialized nature, Spravato must be administered under direct medical supervision in a healthcare setting that is certified under the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program. Innovative MindCare operates as a certified REMS facility, ensuring that every session meets the safety and monitoring standards required by the FDA.

Spravato may be appropriate for adults who have tried two or more antidepressant medications at adequate doses and durations without satisfactory improvement. It is always used in conjunction with an oral antidepressant-not as a standalone therapy. If you have been living with persistent depression that has not responded to standard treatments, Spravato may be worth discussing with a qualified provider.

Step One: Your Initial Evaluation

The Spravato treatment journey at Innovative MindCare begins with a thorough clinical evaluation. This is not a one-size-fits-all process. A qualified provider will review your psychiatric history, current symptoms, past medication trials, and overall health to determine whether Spravato is a clinically appropriate option for you.

What the Evaluation Covers

• A detailed review of your depression history and previous treatments
• Assessment of current depressive symptoms and their severity
• Discussion of your treatment goals and any concerns about the process
• Medical history screening to identify any factors that may affect candidacy
• Coordination with your current prescribing provider, if applicable

This evaluation is a collaborative conversation. The clinical team at Innovative MindCare takes the time to answer questions and ensure that you understand the treatment timeline, what each phase involves, and what outcomes may realistically look like. No treatment is guaranteed to work for every individual, but this initial assessment helps determine whether Spravato has a reasonable chance of helping manage your symptoms.

Insurance Coverage for Spravato

One important consideration during this initial stage is insurance. Unlike some other interventional treatments, Spravato is typically covered by major insurance plans. At Innovative MindCare, accepted insurance providers for Spravato include Aetna, Cigna, Blue Cross Blue Shield, UnitedHealthcare, Medicare, and Medicaid. Patients are encouraged to contact the clinic to confirm their specific coverage details before beginning treatment.

The Induction Phase: Weeks One Through Four

Once a patient is approved to begin Spravato, the treatment enters the induction phase. This is the most intensive portion of the treatment timeline and typically spans the first four weeks. During induction, patients visit the clinic twice per week for supervised Spravato sessions.

The induction phase is designed to introduce the medication at a therapeutic level and allow the clinical team to monitor your response closely. Frequency of sessions during this period is important because Spravato’s mechanism of action may begin to produce noticeable changes in depressive symptoms relatively early in the process, though individual timelines vary. Some patients report beginning to notice shifts in mood within the first few sessions, while for others it may take longer. It is important to approach this phase with realistic expectations-improvement is often gradual and not guaranteed.

What Happens During Each Induction Session

Every Spravato session at Innovative MindCare follows a structured, consistent format to ensure patient safety and comfort:

1. Pre-treatment check-in: Before each session, a member of the clinical team checks your blood pressure and reviews how you have been feeling since your last visit. You will also be asked about food and fluid intake, as patients are generally advised to avoid eating for at least two hours before treatment.
2. Nasal spray administration: Spravato is self-administered by the patient under direct supervision of a healthcare provider. The nasal spray device is used according to the prescribed dosing protocol. Administration typically takes only a few minutes.
3. Monitored observation period: After administration, patients remain in the clinic for a minimum of two hours under observation. During this time, staff monitor blood pressure, sedation levels, and any other effects. Many patients find this period to be calm and uneventful. Some may experience temporary side effects such as dizziness, nausea, dissociation, or elevated blood pressure, which typically resolve within the observation window.
4. Post-session guidance: Patients cannot drive, operate heavy machinery, or engage in hazardous activities for the remainder of the day following treatment. Arranging transportation to and from the clinic is a required part of each visit.

This same session structure applies throughout both the induction and maintenance phases, providing a familiar and predictable experience at every visit.

Transitioning to Maintenance: Sustaining Progress Over Time

After completing the four-week induction phase, patients who are responding to treatment transition into the maintenance phase. This shift reflects a change in session frequency rather than a change in the treatment itself.

Weeks Five Through Eight

During weeks five through eight, session frequency typically decreases to once per week. This tapering allows the clinical team to assess how well symptom improvement is maintained between sessions. Your provider will continue to monitor your progress, adjust dosing if clinically indicated, and discuss how you are feeling overall.

Week Nine and Beyond

Beginning in week nine and continuing forward, sessions generally transition to once every one to two weeks, depending on the individual patient’s response and clinical needs. Some patients may eventually settle into a schedule of sessions every two weeks, while others may benefit from weekly visits for a longer period. This decision is made collaboratively between the patient and their provider at Innovative MindCare.

The maintenance phase is a critical part of the Spravato treatment journey. Depression is a chronic condition, and Spravato is designed to be used as an ongoing treatment alongside an oral antidepressant-not as a short-term intervention with a defined endpoint. Patients who discontinue treatment prematurely may experience a return of depressive symptoms. Consistent follow-up appointments help the clinical team track your trajectory and make adjustments as needed.

What Patients Should Know About the Overall Experience

For individuals considering Spravato treatment in Chicago or Downers Grove, there are several practical points worth keeping in mind as you think about what the journey involves:

• Time commitment: Especially during induction, the twice-weekly schedule requires dedicated time. Each visit lasts approximately two to two and a half hours, including the observation period. Planning ahead for transportation and scheduling is essential.
• Concurrent oral antidepressant: Spravato is always prescribed alongside a traditional oral antidepressant. These medications work together, and continuing your oral antidepressant as directed is a key part of the treatment plan.
• Ongoing communication with your provider: Your experience during and between sessions matters. The team at Innovative MindCare encourages open dialogue about symptom changes, side effects, and any concerns that arise throughout treatment.
• Realistic expectations: Many patients experience meaningful improvement in depressive symptoms with Spravato, but results vary. It is not a cure for depression, and it does not work for everyone. Clinical studies have shown that Spravato, combined with an oral antidepressant, may help reduce depressive symptoms in patients who have not responded to other treatments-but individual outcomes depend on many factors.

One of the advantages of seeking Spravato treatment in Chicago at Innovative MindCare is the continuity of care. Rather than being referred between multiple providers, patients receive their treatment in a consistent clinical environment with a team that knows their history, monitors their progress, and adjusts the plan as their needs evolve.

Why the Structured Journey Matters

The phased structure of Spravato treatment-from evaluation to induction to maintenance-exists for important clinical reasons. The induction phase builds a therapeutic foundation. The maintenance phase preserves and extends any gains. And the ongoing provider relationship ensures that care is never static but always responsive to how you are doing in the present.

Treatment-resistant depression is, by definition, a condition that has not responded to conventional approaches. For patients in this situation, having a clearly mapped treatment pathway can provide both clinical benefit and a sense of direction. At Innovative MindCare, the goal is to make every step of that pathway transparent and well-supported.

Take the Next Step Toward Understanding Your Options

If you are living with treatment-resistant depression and have not found relief through standard antidepressant medications, learning more about Spravato treatment in Chicago may be a worthwhile next step. Innovative MindCare serves patients in Chicago and Downers Grove, Illinois, and the clinical team is available to answer questions, discuss candidacy, and help you understand what the treatment journey would look like for your specific situation.

Contact Innovative MindCare to schedule an initial consultation. A knowledgeable provider can review your history, address your concerns, and help you determine whether Spravato may be an appropriate option for managing your depressive symptoms moving forward.